Brian Stearns, Ph.D.
Chief Scientific Officer
Dr. Stearns is chief scientific officer of Autobahn Therapeutics
Dr. Stearns has a deep wealth of experience in CNS drug discovery, with particular expertise in the field of remyelination. Prior to Autobahn, Dr. Stearns was the co-founder and chief operating officer of Pipeline Therapeutics. He also previously served as the vice president of chemistry at Inception Sciences, a Versant Ventures discovery engine, where he led all aspects of chemistry and DMPK. Dr. Stearns led Inception 5, which was a remyelination company acquired by Roche in 2018. Prior to joining Inception, Dr. Stearns was senior director of chemistry at Amira Pharmaceuticals, contributing to the discovery of several clinical stage small molecule therapeutics to treat inflammation and fibrosis. Prior to that, he was a research fellow at Merck & Co., where he contributed to the discovery of neuropsychiatry and neurology therapeutics. He received a Ph.D. in organic chemistry from the University of California, Irvine, and a B.S. in chemistry from The Ohio State University.